No Data
DWTI, Architects SJ and others.
＜1447＞ Acquisition and cancellation of all remaining subscription rights of the 4th series (with exercise price adjustment clause). ＜3557＞ Massive exercise of the 9th subscription rights of U&C (with exercise price adjustment clause) beginning from the 4th, number of delivered stocks is 0.07 million 2000 shares. ＜4576＞ DWTI obtained approval for the glaucoma and ocular hypertension treatment "Graalpha Combination Eye Drops (domestic product name)" in Thailand. ＜4586＞ Termination of joint research contract with Medrec fanpepp. ＜4881＞ Solexia downward revision, current period profit.
Medrx 9-Mos Loss Y320.00M Vs Loss Y671.00M
Medrx Sees FY Loss Y846.00M
Medrx: Summary of Financial Results for the 3rd Quarter Ending 2024/12 [Japanese GAAP] (Consolidated)
Morinaga Milk, mcdonald's, Toyo Suisan, Eisai (8th) (1429-5463)
※Please note that the above calendar is tentative and subject to change based on the company's convenience. --------------------------------------- November 8th (Fri) <1429> Japan Aqua <1435> RoboHome <143A> Ishin <1450> Tanaka Construction Industry <1451> KHC <1518> Mitsui Matsushima HD <151A> Dai <167A> Ryo
Emerging markets stocks digest: Fulta continues to rise significantly, sea U sea hits the daily limit.
<4598> DELTA-P 533 +47 surged significantly. After the trading on the 28th, the progress of the phase 1/2 clinical trial of DFP-10917 and VEN was announced, which is considered a positive development. DFP-10917, when given as a low-dose continuous infusion, is believed to be highly safe, stops cancer cells in the G2/M phase, and induces apoptosis (programmed cell death). Therefore, a strong synergistic effect can be expected when combined with VEN (a BCL-2 inhibitor). Currently, a phase 1 clinical trial is underway.
No Data